PRMT5 inhibitors are mostly effective against several kinds of carcinomas, such as solid tumors and diffuse large B-cell lymphoma, as well as non-Hodgkin’s lymphoma and AML [15]. The gene discussed is PRMT5; the disease is acute myeloid leukemia.